Biology:Gataparsen
From HandWiki
| Clinical data | |
|---|---|
| Other names | LY2181308 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]
It being investigated for a number of different cancers.[2]
It is targeted at survivin which prevents cells dying.[3]
Clinical trials
It has completed a phase II trial for acute myeloid leukemia.[4]
A phase II trial for non-small cell lung cancer has started.[5]
A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]
References
- ↑ "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology 68 (2): 505–11. August 2011. doi:10.1007/s00280-010-1506-7. PMID 21079959.
- ↑ "Search of: LY2181308". https://clinicaltrials.gov/ct2/results?term=LY2181308.
- ↑ "Cancer". http://www.isispharm.com/Pipeline/Therapeutic-Areas/Cancer.htm.
- ↑ "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". https://clinicaltrials.gov/ct2/show/NCT00620321.
- ↑ "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". https://clinicaltrials.gov/ct2/show/NCT01107444.
- ↑ "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". https://clinicaltrials.gov/ct2/show/NCT00642018.
 |
